作为甲基胺成的目标的β2AR:与TAAR1不同的机制
Yize Wang1, Libo Zhang2, Jie Li3
1State Key Laboratory of Synthetic Biology, Haihe Laboratory of Sustainable Chemical Transformations, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Faculty of Medicine, School of Life Sciences, Tianjin University, Tianjin 300072, China.
Cell reports
|September 24, 2025
概括
甲基胺成涉及β-2上腺体受体 (β2AR),而不仅仅是TAAR1. 阻止β2AR会影响奖励通路中的突触可塑性,这表明它是新的成治疗的关键目标.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 甲基胺 (METH) 成是一种全球性健康问题,其分子基础不明确.
- 已知METH可以向微量胺相关受体1 (TAAR1).
研究的目的:
- 为了确定超出TAAR1.1的METH的新分子标.
- 阐明METH作用的结构机制.
- 调查确定目标在与METH成相关的突触可塑性中的作用.
主要方法:
- 低温电子显微镜和突变发生,以确定受体结构.
- 突触可塑性测定在中等脊状神经元 (MSN) 中的突触可塑性测定.
- 使用选择性β2AR抗剂禅尼多洛尔的药理抑制.
主要成果:
- 确定了β2-上腺素受体 (β2AR) 作为METH点,调解Gs合的cAMP信号传递.
- 结构研究揭示了METH在β2AR和TAAR1.1上的差异性结合和有效性.
- 在NAc外内的D2-MSN中抑制β2AR,但不激活TAAR1,增强激发性输入和GluA1酸化.
结论:
- β2AR是METH成效应的关键调解者,与TAAR1不同.
- 结构和突触可塑性数据提供了β2AR和METH成之间的机制联系.
- 这些发现为开发针对METH成的向治疗提供了基础,重点关注β2AR.
相关概念视频
Drug Abuse and Addiction: Pharmacological Phenomena
1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
Adrenergic Agonists: Indirect-Acting Agents
2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Adrenergic Receptors: β Subtype
3.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.5K
Opioid Receptors: Overview
4.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.1K
Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K


